ABC | Volume 112, Nº1, January 2019

Elias Nero et al ARVC/D - Diagnosis and treatment Arq Bras Cardiol. 2019; 112(1):91-103 Review Article 11. Mizusawa Y. . Recent advances in genetic testing and counseling for inherited arrhythmias. J Arrhythm. 2016;32(5):389-97. 12. van der Zwaag PA, Jongbloed JD, van den Berg MP, van der Smagt JJ, Jongbloed R, Bikker H, et al. A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy. HumMutat. 2009;30(9):1278-83. 13. Corrado D, Zorzi A, Cerrone M, Mongillo RM, Bauce B, Delmar M. Relationship between arrhythmogenic right ventricular cardiomyopathy and Brugada Syndrome: new insights from molecular biology and clinical implications. Circ Arrhythm Electrophysiol. 2016;9(4):e003631. 14. Bhonsale A, Riele ASJM, Sawant AC, Groeneweg JÁ, James CA, Murray B, et al. Cardiac phenotype and long-term prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with late presentation.Heart Rhythm. 2017;14(6):883-91. 15. Ruwald AC, Marcus F, Estes NA 3rd, Link M, McNitt S, Polonsky B, et al. Association of competitive and recreational sport participationwith cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2015;36(27):1735-43. 16. Pinamonti B, Brun F, Mestroni L, SinagraG. Arrhythmogenic right ventricular cardiomyopathy: from genetics to diagnostic and therapeutic challenges. World J Cardiol. 2014;6(12):1234-44. 17. Liu T, Pursnani A, SharmaUC, Vorasettakarnkij Y, Verdini D, Deeprasertkul P, et al. Effect of the 2010 task force criteria on reclassification of cardiovascular magnetic resonance criteria for arrhythmogenic right ventricular cardiomyopathy. J Cardiovasc Magn Reson. 2014 Jul 4;16:47. 18. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/ dysplasia: proposed modification of the task force criteria. Circulation. 2010;121(13):1533-41. 19. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52(25):2175-87. 20. Castanos Gutiérrez SL, Kamel IR, Zimmerman SL. Current concepts on diagnosisandprognosisofarrhythmogenicrightventricularcardiomyopathy/ dysplasia. J Thorac Imaging. 2016;31(6):324-35. 21. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/ dysplasia: proposed modification of the task force criteria. Circulation. 2010;121(13):1533-41. 22. Corrado D, Basso C, Judge DP. Arrhythmogenic cardiomyopathy. Circ Res. 2017;121(7):784-802. 23. Li GL, Saguner AM, Fontaine GH, Frank R. Epislon waves: Milestones in the discovery and progress. Ann Noninvasive Electrocardiol. 2018;23(6):e12571. 24. Tonet JL, Castro-Miranda R, Iwa T, Poulain F, Frank R, Fontaine GH. Frequency of supraventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia. Am J Cardiol. 1991;67(13):1153. 25. Camm CF, James CA, Tichnell C, Murray B, Bhonsale A, te Riele AS, et al. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2013;10(11):1661-8. 26. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/ dysplasia Circulation. 2003;108(25):3084-91. 27. Chung FP, Llin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, et al. Current and state of the art on the electrophysiologic characteristics and catheter ablation of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiol. 2015;65(6):441-50. 28. Bai R, Di Biase L, Shivkumar K, Mohanty P, Tung R, Santangeli P, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/ cardiomyopathy:arrhythmia-freesurvivalafterendo-epicardialsubstratebased mapping and ablation. Circ ArrhythmElectrophysiol. 2011;4(4):478-85. 29. Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol. 2016; 68(4):411-21. 30. Corrado D, Zorzi A, Cerrone M, Rigato I, Mongillo M, Bauce B, et al. Relationship between arrhythmogenic right ventricular cardiomyopathy and Brugada Syndrome: new insights from molecular biology and clinical implications. Circ Arrhythm Electrophysiol. 2016;9(4):e003631. 31. Scheinman MM. Is the Brugada Syndrome a distinct clinical entity? J Cardiovasc Electrophysiol. 1997;8(3):332-6. 32. Zumhagen S, Spieker T, Rolinck J, Baba HA, Breithardt G, Böcker W, et al. Absence of pathognomonic or inflammatory patterns in cardiac biopsies from patients with Brugada Syndrome. Circ Arrhythm Electrophysiol. 2009;2(1):16-23. 33. Frustaci A, Priori SG, Pieroni M, Chimenti C, Napolitano C, Rivolta I, et al. Cardiac histological substrate in patients with clinical phenotype of Brugada Syndrome. Circulation. 2005; 112(24):3680-7. 34. Corrado D,Wichter T, Link MS, Hauer RN, Marchlinski FE, Anastasakis A, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/ dysplasia - an International Task Force Consensus Statement. Circulation. 2015;132(5):441-53. 35. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NA 3rd, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132(22): e 273-80. 36. Tonet J, Frank R, Fontaine G, Grosgogeat Y. Efficacy and safety of low doses of beta-blocker agents combined with amiodarone in refractory ventricular tachycardia. Pacing Clin Electrophysiol. 1988;11(11 Pt 2):1984-9. 37. Ermakov S, Gerstenfeld EP, Svetlichnaya Y, ScheinmanMM.Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2017;14(4):564-9. 38. Philips B, Madhavan S, James C, Tichnell C, Murray B, Dalal D, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2012;5(3):499-505. 39. VermaA,KilicaslanF,SchweikertRA,TomassoniG,RossilloA,MarroucheNF, et al. Short- and long-term success of substrate-basedmapping and ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia. Circulation. 2005;111(24):3209-16. 40. Dalal D, Jain R, Tandri H, Dong J, Eid SM, Prakasa K, et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007;50(5):432-40. 41. Miljoen H, State S, Chillou C, Magnin-Poull I, Dotto P, Andronache M, et al. Electroanatomic mapping characteristics of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Europace. 2005;7(6):516-24. 42. Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. J Am Coll Cardiol. 2014;64(2):119-25. 12